Share on LinkedInShare on LinkedIn

ARTICLE · 16 FEBRUARY 2014

It Might Take Three To Bolar

De Brauw Blackstone Westbroek
De Brauw Blackstone Westbroek
Contributor
De Brauw Blackstone Westbroek

De Brauw Blackstone Westbroek

Our clients are increasingly operating in South-East Asia and require legal assistance in the...

View firm profile
Explore more from De Brauw Blackstone Westbroek

The Düsseldorf Court of Appeal recently challenged established opinion that a third-party’s supply of ingredients to a generic pharmaceutical company for marketing research purposes is not covered by the Bolar exemption.

NetherlandsFood, Drugs, Healthcare, Life Sciences

The Düsseldorf Court of Appeal recently challenged established opinion that a third-party's supply of ingredients to a generic pharmaceutical company for marketing research purposes is not covered by the Bolar exemption. The Düsseldorf Court of Appeal submitted preliminary questions on this issue to the Court of Justice of the European Union (ECJ). The outcome could have implications for ingredient suppliers and the European pharma industry.

Introduction

The issue is whether and under what conditions a third-party's supply of patent-protected substances to a generic pharmaceutical company, which intends to use the substance for research to obtain a marketing authorisation (MA), is covered by the Bolar exemption. Previous decisions in Germany and Poland concerning the same facts ruled that the third-party supplier is not exempted from patent infringement. In December, the Düsseldorf Court of Appeal (CoA) held that a third party should be exempted conditionally, but

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from